Needle-Free semaglutide patch enters first human safety trial

NCT ID NCT07539415

Recruiting now Disease control Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times

Summary

This early-stage trial tests a microneedle patch called DWRX5003 that delivers semaglutide, a drug used for obesity and type 2 diabetes. The study involves 72 healthy adults to check safety and how well the drug enters the body compared to standard injections. It is not yet testing in people with the conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide (in a microneedle patch)
What this could lead to: If successful, this could lead to a needle-free way to deliver semaglutide for weight management and diabetes control.
What could go wrong: This is a very early Phase 1 safety study in healthy volunteers, not patients. The patch may not deliver the drug effectively or could cause skin reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT TYPE 2 DIABETES

Contacts and locations

Locations

Seoul National University Hospital
RECRUITING

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.